Shares of AnaptysBio Inc (NASDAQ:ANAB) have been given an average recommendation of “Buy” by the thirteen analysts that are currently covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $126.60.
Several research analysts have recently commented on ANAB shares. Stifel Nicolaus set a $124.00 price target on AnaptysBio and gave the stock a “buy” rating in a report on Wednesday, May 8th. Zacks Investment Research lowered AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, May 7th. Cantor Fitzgerald set a $140.00 price target on AnaptysBio and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Wedbush reiterated an “outperform” rating on shares of AnaptysBio in a report on Friday, March 1st. Finally, Guggenheim started coverage on AnaptysBio in a report on Friday, February 22nd. They set a “buy” rating and a $135.00 price target on the stock.
Shares of ANAB stock opened at $72.52 on Thursday. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -29.01 and a beta of 2.16. AnaptysBio has a fifty-two week low of $54.26 and a fifty-two week high of $110.00.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.01. As a group, equities research analysts forecast that AnaptysBio will post -3.63 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently bought and sold shares of ANAB. Vanguard Group Inc. increased its position in shares of AnaptysBio by 20.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,851,930 shares of the biotechnology company’s stock worth $184,767,000 after purchasing an additional 308,517 shares during the last quarter. Millennium Management LLC increased its position in shares of AnaptysBio by 11,829.2% during the 4th quarter. Millennium Management LLC now owns 258,624 shares of the biotechnology company’s stock worth $16,498,000 after purchasing an additional 256,456 shares during the last quarter. BlackRock Inc. increased its position in shares of AnaptysBio by 11.7% during the 4th quarter. BlackRock Inc. now owns 1,816,825 shares of the biotechnology company’s stock worth $115,894,000 after purchasing an additional 189,685 shares during the last quarter. Advisor Group Inc. acquired a new stake in shares of AnaptysBio during the 4th quarter worth about $7,827,000. Finally, Norges Bank acquired a new stake in shares of AnaptysBio during the 4th quarter worth about $7,413,000.
AnaptysBio Company Profile
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.
Further Reading: Mutual Funds
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.